Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
- Registration Number
- NCT01939054
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Brief Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR), inhibiting tyrosine kinase activation. This is a randomized, controlled, open-Label, multicenter, phase Ⅱ clinical trial of nimotuzumab plus Docetaxel and Capecitabine（TX）versus Docetaxel and Capecitabine（TX）as first-line treatment in patients with recurrent/metastatic triple negative breast cancer.
- Detailed Description
The control group received docetaxel + capecitabine regimen;Experimental group received Nimotuzumab combined docetaxel + capecitabine regimen.The main purpose is to evaluate Nimotuzumab Plus Docetaxel and Capecitabine（TX）as First-Line Treatment in Patients With Recurrent/Metastatic triple negative breast cancer would improve objective response rate (ORR ) comparing with Docetaxel and Capecitabine（TX）.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 90
- Histological and immunohistochemistry (IHC) confirmed recurrent or metastatic triple-negative breast cancer .
- Previous chemotherapy should include anthracycline or taxane; No prior chemotherapy after metastasis.
- Females with age between 18 and 70 years old
- ECOG performance status 0 or 1.
- At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST) by magnetic resonance imaging, or computed tomography; The target lesions is Unresectable; The target lesions did not receive radiotherapy or relapse within the radiation field;
- Life expectancy ≥ 12 weeks.；
- WBC count ≥ 4 × 109 / L, neutrophils ≥ 1.5 × 109 / L, platelet count ≥ 100 × 109 / L, hemoglobin ≥ 6.21mmol / L (10 g / dL);
- Total bilirubin (TBL)≤ 1.5 x ULN (upper limit of normal reference values); AST and ALT ≤ 2.5 x ULN or ≤ 5 ULN (Liver metastasis);Serum creatinine ≤ 1.5 x ULN.
- Before enrollment, patients have fully recovered from previous treatment-related toxicity;
- Subjects with fertility must accept effective contraceptive measures;
- Signed informed consent
- Previously treatment regimen including anti EGFR monoclonal antibody;
- Receiving other anti-cancer medicine treatment during the study
- Participate in other clinical trials within 4 weeks in this group;
- Accepted taxane treatment in 1 year;
- Presence of neurological symptoms due to brain metastasis, patients receiving steroidal anti-edema drugs therapy;
- Patients having a history of clinically significant symptomatic angina, arrhythmia or congestive heart failure without control;
- Diagnosed with severe interstitial pneumonitis or pulmonary fibrosis by chest CT;
- Pleural effusion, ascites require to be drained;
- Adverse drug addiction and drug abuse, long-term alcoholics, as well as AIDS patients; patients with severe or uncontrolled complications, such as infection requiring systemic therapy, fever (≥ 38 ℃), diabetes or hypertension can not be controlled by medicine, other complications may interfere with drug therapy;
- Patients with a history of drug allergy (≥ CTCAE 2 level) such as shock or allergic symptoms, especially have allergic reactions to similar drugs in the past, have severe allergies reactions to drugs containing polysorbate eighty (Tween 80);
- Uncontrolled seizures or loss of insight due to mental disorders;
- Pregnant or lactating women；
- Researchers think improper for this trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Nimotuzumab,docetaxel,capecitabine docetaxel Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14 docetaxel,capecitabine capecitabine Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14 Nimotuzumab,docetaxel,capecitabine Nimotuzumab Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14 Nimotuzumab,docetaxel,capecitabine capecitabine Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14 docetaxel,capecitabine docetaxel Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
- Primary Outcome Measures
Name Time Method ORR every six weeks, up to 1 year Evaluation ORR every six weeks,with RECIST 1.1.
- Secondary Outcome Measures
Name Time Method Number and ratio of AEs up to 1 year Observe and record AEs when AEs occurred
PFS every six weeks, up to 1 year Relationship of tissue/serum EGFR between efficacy and prognosis 1 year every 6 weeks
Trial Locations
- Locations (9)
Xijing Hospital
🇨🇳Xi-an, Shanxi, China
The General Hospital of the People's Liberation Army (PLAGH)
🇨🇳Beijing, Beijing, China
Beijing cancer hospital
🇨🇳Beijing, Beijing, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
🇨🇳Beijing, Beijing, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, Heilongjiang, China
FuDan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China
Liaoning Cancer Hospital and Institute
🇨🇳Shenyang, Liaoning, China
The First Affiliated Hospital of College of Medicine, Zhejiang University (First Hospital of Zhejiang Province)
🇨🇳Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China